Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 10Colorectal Neoplasms 5Stomach Neoplasms 3Rhabdomyosarcoma 3Osteosarcoma 3Biliary Tract Neoplasms 3Sarcoma, Ewing 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Wilms Tumor 1Small Cell Lung Carcinoma 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1Rectal Cancer Patients 1Peritoneal Neoplasms 1PDAC - Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Metastatic Gastric Adenocarcinoma 1Metastatic Adenocarcinoma of the Pancreas 1Malignant Ascites 1Hepatoblastoma 1Gastrointestinal Neoplasms 1Gastroesophageal Junction Adenocarcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

irinotecan sucrosofate 1Oxaliplatin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Small Intestine Cancer × irinotecan sucrosofate × 1 year × Clear all
NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

The Methodist Hospital Research Institute

Phase 1 Not yet recruiting
22 enrolled
Gastrointestinal

Advanced Small Intestine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡